Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.95 |
| ▸ | SCN5A | Q14524 | 7/20 | 0.95 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12012325 | 0.99 | KCNH2 (0.93) | KCNH2SCN5ACARM1PRMT6 | |
| Oxalic Acid SCHEMBL3525882 | 0.96 | KCNH2 (0.87) | KCNH2SCN5A | |
| Oxalic Acid SCHEMBL3520564 | 0.95 | KCNH2 (0.86) | KCNH2SCN5A | |
| SCHEMBL3521622 | 0.84 | KCNH2 (0.77) | KCNH2SCN5ACARM1PRMT6 | |
| SCHEMBL3525454 | 0.82 | KCNH2 (0.71) | KCNH2SCN5ACARM1PRMT6 | |
| SCHEMBL12012328 | 0.81 | KCNH2 (0.72) | KCNH2SCN5A | |
| SCHEMBL3520608 | 0.81 | KCNH2 (0.69) | KCNH2SCN5ACARM1PRMT6 | |
| SCHEMBL3522504 | 0.79 | KCNH2 (1.00) | KCNH2SCN5A | |
| SCHEMBL12012283 | 0.79 | KCNH2 (0.68) | KCNH2SCN5ACARM1PRMT6 | |
| SCHEMBL12012327 | 0.78 | KCNH2 (0.73) | KCNH2SCN5ACARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2241567-A1 | BICYCLOAMINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | KCNH2 3/4885SCN5A 11/4885CARM1 2528/4885 |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | KCNH2 3/4885SCN5A 11/4885CARM1 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.